Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atrasentan in type 2 diabetes mellitus with diabetic nephropathy
NL-OMON44825Phase 3Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Apr 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in diabetic glomerulosclerosis and type 2 diabetes mellitus (T2DM) comparing Atrasentan with Placebo (2 arms). Primary endpoint: Primary renal composite endpoint. Started Apr 2014; status: active, not recruiting.
02
Drugs
atrasentan
03
Conditions
diabetic glomerulosclerosistype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NL-OMON44825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44825.